SEARCH

SEARCH BY CITATION

In this issue, Havrilesky and colleagues argue that the biologic diversity of ovarian cancer means that it will be even harder than expected to save lives through screening. Empirical results from the current randomized clinical trials will provide the strongest evidence about the potential for reducing ovarian cancer death through screening.